Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada
Abstract Background Treatment guidelines suggest either a low-dose or high-dose approach when prescribing amikacin for nontuberculous mycobacterial pulmonary disease (NTM PD), but data supporting the low-dose approach are limited. The purpose of this study was to describe the safety and efficacy of...
Main Authors: | Maria Luisa Aznar, Theodore K. Marras, Ahmed Said Elshal, Mahtab Mehrabi, Sarah K. Brode |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | BMC Pharmacology and Toxicology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40360-019-0302-1 |
Similar Items
-
Nontuberculous mycobacterial axillary lymphadenitis in children
by: Jerome A. Lindeboom, et al.
Published: (2021-05-01) -
Costs Associated with Nontuberculous Mycobacteria Infection, Ontario, Canada, 2001–2012
by: Lauren C. Ramsay, et al.
Published: (2020-09-01) -
Pulmonary nontuberculous mycobacterial disease in Florida and association with large-scale natural disasters
by: Shweta Kambali, et al.
Published: (2021-11-01) -
Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings
by: Morita A, et al.
Published: (2022-07-01) -
Preliminary Data Regarding the Nontuberculous Mycobacteria Isolation from Clinical Specimens, from Human PatienTS, in Iași County
by: Ioana Alexandra RĂȚOI (ANTON), et al.
Published: (2018-05-01)